Articles tagged with Pharmacology
A University of Houston professor has received funding to develop effective treatments for Cryptosporidium infections, which cause severe diarrhea and have no existing cure. The team aims to design drugs that target the parasite's enzyme CDPK1 to minimize systemic exposure and maximize efficacy.
A new MOF, APF-80, enables the crystalline sponge method to capture and analyze nucleophilic compounds like alkaloids. This development opens possibilities for structural analysis in drug development and biochemistry.
The ASPIRE trial is a Phase III clinical study investigating whether adding chemotherapy to standard treatments can extend survival in men with advanced prostate cancer. The trial aims to determine the effectiveness of combining docetaxel with hormone therapy and apalutamide.
Researchers at Korea University College of Medicine found that the c-Kit protein helps protect sweet-sensing taste cells from nerve damage, allowing them to survive and regenerate. This discovery may lead to new approaches for improving nutrition, supporting patients with taste disorders, and advancing flavor science.
Researchers found that combination of drugs effectively reduce fat accumulation in laboratory animal models of metabolic liver disease. The study suggests that this combination may also help reduce both liver involvement and associated cardiovascular complications.
Researchers argue that AI can strengthen pandemic preparedness by detecting emerging diseases earlier. By combining data from humans, animals, and the environment, AI can reveal patterns and provide insights into potential pathogens.
Scientists at the University of Liverpool have developed a low-cost, AI-powered blood test that measures key biomarkers of Alzheimer's disease in the blood with accuracy similar to expensive hospital-based tests. The device is powered by artificial intelligence and can be used instantly without specialist training.
Researchers developed COOKIE-Pro, a data analysis method for covalent inhibitors, to measure binding strength and reaction speed against thousands of proteins simultaneously. The technique promises to accelerate therapeutics design by precisely measuring affinity and reactivity.
A study published by TTUHSC researchers found that the blood-brain barrier remains intact in a commonly used mouse model of Alzheimer's disease, suggesting that drug delivery strategies may need to be redesigned. The discovery challenges long-standing assumptions about the impact of Alzheimer's on the brain's protective shield.
Researchers have made significant strides in understanding osteoarthritis by identifying five hub genes that show high diagnostic performance. These genes, including IGKC, MCL1, and NFKBIA, are predicted to be targeted by several drugs, including rapamycin and Sodium_salicylate.
Published by Far Publishing Company, Current Pharmaceutical Analysis (CPA) provides a platform for researchers to share their latest findings. The journal focuses on drug discovery to clinical application, aiming to advance every aspect of pharmaceutical science.
Current Molecular Pharmacology is a prominent journal covering mechanisms of new drugs, innovative technologies, and omics applications. It has an impact factor of 2.9 and CiteScore of 5.5, ranking Q2 in pharmacology.
A new study decodes the mechanism of glioblastoma's resistance to chemotherapy by identifying a HIF-independent circuit built around the epigenetic enzyme PRMT2. Researchers found that combining an existing orphan drug with standard chemotherapy can overcome this resistance, doubling survival without added toxicity.
Researchers identified a promising treatment for PTSD, chronic pain, and alcohol misuse in rats. The study found that PPL-138 selectively reduced anxiety-like behavior, pain responses, and alcohol consumption in those with trauma-related anxiety.
A study found that lactate IV infusion increases brain-rejuvenating hormone BDNF levels in the bloodstream, similar to those after high-intensity exercise. The hormone promotes nerve cell growth and survival. Researchers suggest moderate exercise may be necessary for optimal benefits.
Pharmacy technicians alleviate clinicians' and nurses' workload by handling medication tasks, reducing pain points in medication access work. The study found that technicians improved perceptions of quality of care and patient access, with significant reductions in burden and task time.
A smartphone app, Med Safety, improved the reporting of suspected adverse drug reactions (ADRs) by 73% among healthcare workers in Uganda. This landmark trial provides robust evidence for digital pharmacovigilance systems in low- and middle-income countries.
A large international clinical trial found that elinzanetant significantly reduces hot flashes and night sweats in postmenopausal women by over 73%. The drug also shows secondary benefits such as improved quality of life and reduced sleep disturbances, with no harmful effects on the liver or bone density.
Researchers at the University of Liverpool have discovered a groundbreaking new class of antibiotics called Novltex, which targets lipid II in bacterial cell walls. This innovative approach offers potent and durable protection against multidrug-resistant bacteria, addressing one of the biggest challenges in modern medicine.
A randomized clinical trial shows that low-dose aspirin reduces the risk of recurrence by 55% in patients with colon and rectal cancer harboring a specific genetic mutation. Aspirin's anti-inflammatory and anti-tumor effects may be responsible for its therapeutic benefits.
Researchers at DTU have discovered a way to combat antibiotic-resistant bacteria by nourishing special bifidobacteria that is naturally occurring in the gut. Special lactic acids produced by bifidobacteria play a key role in keeping antibiotic-resistant bacteria at bay.
The Alliance for Clinical Trials in Oncology will host a public webinar showcasing key findings from the 2025 ASCO Annual Meeting. Researchers will discuss latest information on colorectal, squamous cell, and renal cell cancers.
A collaborative team from Texas Tech University Health Sciences Center has received a five-year, $2.9 million R01 grant and a competitive renewal of $3 million to explore therapies for ischemic stroke. The team aims to develop medications that mimic the brain's self-protective mechanisms.
The conference focused on accelerating drug development for rare diseases, neurology, type-1 diabetes, and pediatrics, with a focus on patient-centered evidence generation. Key commitments included early interception, trial modernization, and patient-first approaches.
Researchers evaluated a tool based on NCCN Guidelines to identify high-risk medications and their association with frailty and outcomes in over 380,000 older adults diagnosed with cancer. The study found that each additional high-risk medication increased the odds of being mildly or moderately-to-severely frail by 66%.
A new study from Mizzou's College of Veterinary Medicine analyzed the effects of radioactive iodine therapy on thyroid cancer in dogs. The research found that tailoring the dose of radiation more precisely for each dog could improve outcomes and potentially lead to more targeted care.
Scientists developed hollow microspheres with adjustable pore size, adhesion, and lubricity properties using mucus and polydopamine. These spheres can be used as drug delivery agents and may prevent tissue damage or provide a protective coating.
Ibezapolstat, a new antibiotic, has been shown to be effective in treating Clostridioides difficile (C. diff) infections with high rates of sustained clinical cures. The study found that ibezapolstat killed harmful bacteria without harming the good bacteria in the gut, which helps prevent recurrent C. diff infections.
Researchers Jeremy McCormack and Andrei Kuzhelev at Goethe University are investigating the reasons behind prehistoric shark extinctions using new isotopic analysis methods. They also develop a novel nuclear magnetic resonance spectroscopy technique to study large biomolecules.
Researchers analyzed 5 years of Yellow Card data on 13 drugs containing fluorine and found no significant correlation between fluorine content and adverse drug reactions. The study suggests that the way a drug acts is more likely to result in an adverse reaction, rather than the presence of fluorine.
Professor Gregor Hasler's pioneering research reveals how psychedelics like LSD, psilocybin, and MDMA enhance neuroplasticity, allowing the brain to rewire itself and break free from depression, PTSD, and addiction. His discoveries have the potential to fundamentally alter international approaches to mental health treatment.
A synthetic molecule called Pep19 has been shown to reduce visceral fat and improve sleep quality in overweight adults, with no side effects observed. The study involved 24 volunteers who took either a placebo or Pep19 in capsules, and found a 17% reduction in visceral fat and improved sleep quality in those who received the molecule.
A new approach to the Chan-Evans-Lam reaction enables the synthesis of multiple natural products, including novel vinylic ethers. This breakthrough expands the potential for complex, biologically active compounds in drug research.
Dr. Harriet de Wit's groundbreaking research bridges animal and human drug studies, demonstrating that MDMA enhances feelings of social connectedness and challenging addiction treatment strategies. Her discoveries have profound implications for treating trauma-related disorders globally.
The American Thyroid Association has released new guidelines for managing adult patients with differentiated thyroid cancer, emphasizing evidence-based recommendations for diagnosis, treatment, and monitoring. The guidelines highlight the importance of patient-reported outcomes and areas for further research.
Research reveals neuroglia play active role in brain function, driving disease progression through atrophy and functional decline. Therapeutic strategies targeting neuroglial signaling may prevent damage following brain injury or protect against neurodegenerative processes.
Research from the University of South Australia finds that ibuprofen and paracetamol drive antibiotic resistance when used individually, but amplifying it when combined. The study also reveals that common bacteria like E. coli become highly resistant to antibiotics and multiple other medications.
Researchers at the University of Navarra have developed FLIP-HEDOS, a model that simulates how much radiation blood absorbs during cancer treatment. The study highlights the importance of protecting blood from radiation, which can impair immune function and lead to hematologic toxicity.
Researchers at Mizzou have identified two tiny molecules, agmatine and thiamine, that may serve as biomarkers for early detection of glaucoma. These metabolites could also be used to develop new neuroprotective treatments, aiming to slow or stop the progression of vision loss.
A new imaging approach allows researchers to visualize how dual-acting diabetes and obesity drugs like tirzepatide interact with cells in the pancreas and brain. The tool, called daLUXendins, provides insight into the metabolic effects triggered by these drugs, which stimulate both GLP-1R and GIPR receptors.
Researchers at the University of Waterloo have developed a novel method using modified M13 bacteria to deliver targeted gene therapies for genetic disorders. This approach shows promise as a cost-effective alternative to current methods, which can be expensive and trigger toxic side effects.
Researchers at the University of Oklahoma have made a significant breakthrough in understanding the amylin hormone, which controls appetite and blood sugar. Their findings provide new tools for drug development, enabling pharmaceutical companies to target specific receptors with greater precision.
Researchers from Australia and China have found nine high-priority pathogens in aircraft lavatory wastewater, including some resistant to multiple drugs. The study suggests that monitoring aircraft wastewater could provide an early warning system for the spread of antimicrobial-resistant superbugs.
UGA researchers have developed a long-lasting hand sanitizer alternative called NORel that eliminates more than 97% of bacteria and fungi. The gel formula maintains effective antimicrobial activity for up to two hours after application, making it promising for high-risk environments.
Researchers designed over 36 million compounds using generative AI algorithms and computationally screened them for antimicrobial properties. The top candidates show promise against Neisseria gonorrhoeae and Staphylococcus aureus (MRSA) by novel mechanisms that disrupt bacterial cell membranes.
Researchers created a glycan-binding protein that can analyze and treat diseases via sugar patterns found on the surface of cells. The tool, named sCore2, was developed by retraining an enzyme to bind to specific sugars, providing a new way to study glycans and their role in disease.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
A hospital imaging technique can monitor atherosclerosis by measuring cellular metabolism within arterial plaques. The study demonstrates that the FDG-PET signal reflects the metabolic activity of atherosclerotic plaques, enabling sensitive evaluation of treatment efficacy and disease progression risk.
BU researchers Hui Feng and Venetia Zachariou have received a $2.1 million NIH grant to fund a five-year training program in biomolecular pharmacology. The program aims to prepare the next generation of independent investigators through individualized and multidisciplinary research training.
The new handbook provides a practical approach to harnessing zebrafish as a model organism for biomedical research, covering drug efficacy evaluation and disease mechanisms. It offers step-by-step experimental protocols and theoretical grounding for researchers of all levels.
A novel approach combining chemotherapy, immunotherapy, and a MET inhibitor enhances treatment response and limits tumor growth in small cell lung cancer (SCLC). The strategy slows tumor progression and improves survival outcomes by facilitating the effectiveness of standard treatment.
A groundbreaking cancer drug, KCL-HO-1i, has shown promise in making chemotherapy-resistant cancers more responsive to therapy by targeting a key defence mechanism used by tumours. In preclinical models, the drug has already demonstrated effectiveness in laboratory tests using mouse models of breast cancer.
Researchers developed a deep learning model to predict ADRs using molecular structures, achieving high accuracy in detecting rare effects and minimal risk for novel molecules. The model demonstrated potential as a decision-support tool in early-phase drug discovery and regulatory safety monitoring.
A new study found antimicrobial resistant bacteria spreading rapidly among children with severe malnutrition in Niger. The bacteria can cause life-threatening infections like pneumonia and sepsis, which are difficult to treat with antibiotics.
Researchers conducted a randomized clinical trial to compare low- and high-dose methylprednisolone with azithromycin for treating severe Mycoplasma pneumoniae pneumonia. The study found that lower dose regimen of glucocorticoids is sufficient, equally effective, and safer than the high dose regimen.
Researchers validated panels of antibodies targeting clinically relevant nucleic acid modifications to visualize antisense oligonucleotides in both in vitro and in vivo studies. The tools enable detection of modified nucleic acids irrespective of sequence, facilitating multiple clinical and pre-clinical workflows.
A new treatment for corneal scarring is being developed by University of Houston optometry researcher Tarsis G. Ferreira. The treatment uses a natural protein called decorin to block scarring and unwanted blood vessel growth, offering hope for people with injured corneas.
Researchers discovered complex structures in millipede secretions that can modulate specific neuroreceptors in ant brains, shedding light on potential new medications. The newly found alkaloids, named andrognathanols and andrognathines, have shown potent interactions with the Sigma-1 neuroreceptor.
The 2025 Critical Path Institute Global Impact Conference will bring together industry, regulatory agencies, academia, and patient advocacy groups to discuss pressing challenges in drug development. The event aims to foster cross-sector collaboration to advance medical innovation and improve treatment outcomes for patients.
Research warns that GLP-1 drugs may not provide the long-term health benefit of improved heart and lung function. While they help with weight loss, patients may experience significant muscle loss, which can increase cardiovascular disease risk. Doctors are urging additional research to better understand the effects of these drugs.